MedTrace Logo

A Prospective Clinical Study Aimed to Assess the Technical Feasibility of RR2 Wearable Home Care Neuromodulation System

NCT04580953 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-02-22

No results posted yet for this study

Summary

RR2 is a medical, home-care, digital therapeutic, wearable device. Its main purpose is to deliver prescheduled, non-invasive, peripheral neuromodulation therapy, in conjunction with standard medical care, to relieve AF symptoms, recurrence and overall burden.

Conditions

  • Atrial Fibrillation Recurrence

Interventions

DEVICE

CardiaCareTM RR2

Treatment with CardiaCareTM RR2

Sponsors & Collaborators

  • Ziv HealthCare Ltd.

    lead INDUSTRY

Principal Investigators

  • Avi Sabbag, MD · Sheba Medical Center

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2022-01-02
Completion
2022-01-02

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04580953 on ClinicalTrials.gov